Shire (NASDAQ:SHPG) has been assigned a $222.00 price objective by research analysts at Cantor Fitzgerald in a research report issued on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 52.75% from the company’s current price.

A number of other research analysts have also recently commented on the company. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Shire in a research report on Thursday, November 16th. Liberum Capital raised Shire from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. FBR & Co reaffirmed a “buy” rating and set a $201.00 price target on shares of Shire in a research report on Monday, October 30th. Cowen set a $225.00 price target on Shire and gave the company a “buy” rating in a research report on Sunday, October 29th. Finally, Zacks Investment Research raised Shire from a “sell” rating to a “hold” rating in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. Shire currently has an average rating of “Hold” and a consensus price target of $212.18.

Shire (NASDAQ:SHPG) traded down $2.91 during mid-day trading on Tuesday, reaching $145.34. The company’s stock had a trading volume of 780,600 shares, compared to its average volume of 1,140,259. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. Shire has a twelve month low of $137.17 and a twelve month high of $192.15. The stock has a market capitalization of $44,538.30, a PE ratio of 10.20, a P/E/G ratio of 0.82 and a beta of 1.59.

Shire (NASDAQ:SHPG) last posted its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire had a return on equity of 14.41% and a net margin of 10.95%. The business had revenue of $3.70 billion for the quarter. During the same period in the prior year, the firm posted $3.17 EPS. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. equities research analysts forecast that Shire will post 15 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in SHPG. YorkBridge Wealth Partners LLC increased its position in shares of Shire by 81.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 317 shares during the last quarter. BB&T Investment Services Inc. grew its position in Shire by 1,672.3% during the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 786 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new position in Shire during the 3rd quarter worth approximately $159,000. Pacer Advisors Inc. bought a new position in Shire during the 2nd quarter worth approximately $171,000. Finally, Stephens Inc. AR grew its position in Shire by 22.2% during the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 228 shares during the last quarter. Hedge funds and other institutional investors own 20.28% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/12/05/shire-shpg-given-a-222-00-price-target-by-cantor-fitzgerald-analysts.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.